Eli Lilly and Company(LLY) Stock Research - Grey Stern Research

Eli Lilly and Company (LLY) Stock Analysis

$836.28 (2.82%)

LLY Financial Performance


Use the table below to view Eli Lilly and Company's financial profile. This data is gathers from the latest available financial statements. Annual data is taken from the trailing 12 months of statements. All numbers are reported in US Dollars and so any foreign currencies are converted to USD so comparison's can be done.

Based on Financial Statements from Q3 - 2024

Metric Value Ranking among Peers
Price $813.33 -
52 Week Low $561.65 -
52 Week High $972.53 -
Market Cap $772.1 Billion 1/8
Gross Margin 81% 2/8
Profit Margin 8% 8/8
EBITDA margin 20% 7/8
Q3 - 2024 Revenue $11.4 Billion 6/8
Q3 - 2024 Earnings $970.3 Million 8/8
Q3 - 2024 Free Cash Flow -$458.9 Million 8/8
Trailing 4 Quarters Revenue $40.9 Billion 6/8
Trailing 4 Quarters Earnings $8.4 Billion 3/8
Quarterly Earnings Growth 1790% 1/8
Annual Earnings Growth 60% 3/8
Quarterly Revenue Growth 20% 3/8
Annual Revenue Growth 330% 1/8
Cash On Hand $3.4 Billion 5/8
Short Term Debt $2.1 Billion 5/8
Long Term Debt $29.0 Billion 6/8

Eli Lilly and Company Financial Metrics


Financial metrics are a set of useful numbers that can give key performance indicators of a company. The various metrics can include information about profitability, growth, and debt load. When combined and use properly they can tell an analyst a compelling fact-based story of how the company is currently performing. To compare Eli Lilly and Company's metrics versus it's peers make sure to run our peer analysis tool.

Valuation Metrics

Metric Value Ranking among Peers
PE 92.25 2/8
PS 18.89 1/8
PB 53.92 1/8
PC 229.18 1/8
Liabilities to Equity 4.30 4/8
ROA 0.11 2/8
ROE 0.59 2/8
Current Ratio 1.23 4/8
Quick Ratio 0.06 7/8
Long Term Debt to Equity 2.04 4/8
Debt to Equity 2.19 4/8
Burn Rate 4.74 3/8
Cash to Cap 0.00 6/8
CCR -0.47 8/8
EV to EBITDA 355.82 1/8
EV to Revenue 19.57 1/8

Company Details

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.

CEO: Mr. David Ricks

Website: https://www.lilly.com

Address: Lilly Corporate Ctr, Drop Code 1094, Lilly Corporate Ctr Indianapolis, INDIANA

Exchange: New York Stock Exchange

Industry: Drug Manufacturers—General

Eli Lilly and Company Peer Analysis


A useful and more reliable way of seeing the health of a company is to compare it to other companies operating in the same sector. Below is our list of companies which we rank are the closest peers to Eli Lilly and Company. If you feel that peers should be added or removed from this list please contact us. To run an in-depth peer analysis which compares many financial metrics click on the link below.

Stock Ticker Market Cap
Pfizer Inc. PFE $144.8 Billion
Bristol-Myers Squibb Company BMY $119.0 Billion
Gilead Sciences, Inc. GILD $115.3 Billion
AbbVie Inc. ABBV $320.7 Billion
Merck & Co., Inc. MRK $257.6 Billion
Johnson & Johnson JNJ $366.8 Billion
Amgen Inc. AMGN $149.6 Billion
Run Peer Analysis
Income Statement
Balance Sheet
Cash Flow Statement
LLY Income Statements
Quarter Year Revenue Earnings
Q3 2024 $ 11.4 Billion $970.3 Million
Q2 2024 $ 11.3 Billion $3.0 Billion
Q1 2024 $ 8.8 Billion $2.2 Billion
Q4 2023 $ 9.4 Billion $2.2 Billion
Q3 2023 $ 9.5 Billion -$57.4 Million
Q2 2023 $ 0 $1.8 Billion
Q1 2023 $ 7.0 Billion $1.3 Billion
Q4 2022 $ 7.3 Billion $1.9 Billion

View All

LLY Balance Sheets
Quarter Year Cash & Equivalents Total Assets Total Debt Total Equity
Q3 2024 $3.4 Billion $75.6 Billion $31.1 Billion $14.3 Billion
Q2 2024 $3.2 Billion $71.9 Billion $28.9 Billion $13.6 Billion
Q1 2024 $2.5 Billion $63.9 Billion $26.2 Billion $12.9 Billion
Q4 2023 $2.8 Billion $64.0 Billion $25.2 Billion $10.9 Billion
Q3 2023 $2.4 Billion $57.9 Billion $20.2 Billion $11.3 Billion
Q2 2023 $2.7 Billion $54.8 Billion $18.8 Billion $11.1 Billion
Q1 2023 $3.5 Billion $53.2 Billion $18.9 Billion $11.2 Billion
Q4 2022 $2.1 Billion $49.5 Billion $16.2 Billion $10.6 Billion

View All

LLY Cash Flow Statements
Quarter Year freeCashFlow capitalExpenditure netChangeInCash
Q3 2024 -$458.9 Million -$4.2 Billion $145.4 Million
Q2 2024 $63.4 Million -$1.4 Billion $763.4 Million
Q1 2024 $179.7 Million -$986.3 Million -$358.4 Million
Q4 2023 -$2.0 Billion -$1.7 Billion $437.8 Million
Q3 2023 $0 $0 $0
Q2 2023 $0 $0 $0
Q1 2023 $827.1 Million -$903.5 Million $1.5 Billion
Q4 2022 $1.0 Billion -$555.6 Million -$550.4 Million

View All

Cookies

We use cookies to offer a better browsing experience. Cookies enhance site navigation, analyze site usage, and assist in our marketing efforts. By clicking Accept. you agree to the storing of cookies on your device. To refuse all non-required cookies, click on Decline.

Accept View Terms & Conditions